Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

UnitedHealth Group

Eli Lilly & Co. and UnitedHealth Group Inc. said Friday they are joining forces for a study of Lilly's bamlanivimab in high-risk, COVID-19 infected patients. Bamlanivimab is an antibody treatment that recently won U.S. Food and Drug Administration emergency use authorization as a treatment for mild to moderate COVID-19 patients, who are at high risk of getting a severe case of the virus and/or requiring hospitalization.

Eli Lilly and UnitedHealth to study Lilly's antibody treatment bamlanivimab in high-risk COVID patients

INDIANAPOLIS and MINNETONKA, Minn., Dec. 4, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UnitedHealth Group (NYSE: UNH) today announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals. Bamlanivimab recently...

Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19

With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).

Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US

INDIANAPOLIS, Dec. 2, 2020 /PRNewswire/ -- The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5 million and the doses will be delivered through January...

Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19

Eli Lilly and Company (LLY) Management on Evercore ISI 3rd Annual HealthCONx - Earnings Call Transcript

AstraZeneca

BioNTech SE

Gilead Sciences

Moderna

Pfizer

Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.

COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap

INDIANAPOLIS, Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020. Michael Mason, Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate...

Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference

Let's see if Eli Lilly and Co (LLY) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Choose Eli Lilly and Co (LLY) Stock?

Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.

Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada

Regeneron Pharmaceuticals

A COVID-19 vaccine appears to be just around the corner, and many of the companies developing drugs, cocktails, vaccines and treatments are very close to crossing the finish line.

With a Vaccine Coming Soon, Where Do These COVID-19 Stocks Stand?

Eli Lilly and Company (LLY) Presents Tirzepatide SURPASS Program Overview Conference (Transcript)

INDIANAPOLIS, Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a treatment for adults and pediatric patients...

Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19

Incyte

Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.

Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19

Shares of Eli Lilly & Co. gained 0.6% in premarket trading on Friday, the day after the Food and Drug Administration granted an emergency use authorization to the company's rheumatoid arthritis drug Olumiant as a COVID-19 treatment if it's used in combination with Gilead Sciences Inc.'s Veklury, which is also called remdesivir. The drug combination can be used in adults and children older than 2 years old who have been hospitalized with COVID-19 and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.

Lilly's arthritis drug and Gilead's Veklury receive FDA authorization as combination COVID-19 treatment

Precision Biosciences

INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the...

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug baricitinib has been issued an emergency use authorization, in combination with Gilead Sciences, Inc's (NASDAQ: GILD) remdesivir, for the treatment of COVID-19 in adults and children who are hospitalized and require supplemental oxygen and other supportive ventilation measures.  What Happened: The Food and Drug Administration said in a statement that baricitinib — sold under the brand name Olumiant — led to recovery within 29 days of initiating treatment compared to patients who only received remdesivir, in a clinical trial of hospitalized patients with COVID-19.

Eli Lilly's Arthritis Drug Gets Emergency Use Approval For Treatment Of COVID-19

This is the first drug combination given emergency approval by the FDA for the coronavirus.

FDA Gives Emergency Approval To Covid-19 Treatment That Combines Eli Lilly Arthritis Drug With Remdesivir

INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in...

Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19

Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.

What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?

BURGDORF, Switzerland and INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions. Under the...

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Eli Lilly and Company (LLY) Presents at Wolfe Research Virtual Healthcare Conference (Transcript)

Eli Lilly & Company stock is up 7% since the start of the year and it has gained around 19% from its March lows. LLY stock could offer an upside in the near term, as the company's revenues in the last two quarters have grown by 1%.

Covid-19 Treatment Approval To Drive Eli Lilly Stock Higher?

American hospitals may have to ration Eli Lilly & Co.'s new COVID-19 treatment as the rapid spread of the virus strains their limited supplies, according to a new report. Hospitals and medical groups are considering giving the antibody drug — which was cleared for emergency use last week — only to people with multiple coronavirus.

Hospitals may limit access to Eli Lilly COVID-19 treatment

The shares of Eli Lilly And Co (NYSE:LLY) are up 0.6% at $141.34 at last check.

Signal Says Pharmaceutical Stock Has Room to Run

U.S. hospitals, weighing high demand and tight supplies, said they may limit use of a new Eli Lilly and Co antibody drug to COVID-19 patients with multiple risk factors for serious illness or to those whose immune systems have not begun to fight the infection. The treatment, bamlanivimab, was given U.S. emergency use authorization (EUA) last week by the Food and Drug Administration for helping newly-diagnosed, high-risk patients avoid hospitalization.

News for Eli Lilly Stock (LLY)